Sonnet Biotherapeutc Hldng Inc Financials
This page shows Sonnet Biotherapeutc Hldng Inc (SONN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not product revenue, is the main engine sustaining research spending and year-end liquidity.
FY2025 looked sturdier because cash ended at$5.1M and equity turned positive at$10.8M . But that repair came from financing cash flow of$26.0M while operations still used$12.8M , which means the balance sheet improved faster than the business became self-funding or commercially scaled.
The cost base still resembles a development-stage platform: FY2025 revenue was only
Losses are also showing up as real cash use. In FY2025, operating cash outflow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sonnet Biotherapeutc Hldng Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sonnet Biotherapeutc Hldng Inc has an operating margin of -1584.4%, meaning the company retains $-1584 of operating profit per $100 of revenue. This below-average margin results in a low score of 2/100, suggesting thin profitability after operating expenses. This is up from -63617.9% the prior year.
Sonnet Biotherapeutc Hldng Inc carries a low D/E ratio of 0.38, meaning only $0.38 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 65/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.50, Sonnet Biotherapeutc Hldng Inc holds $3.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.
Sonnet Biotherapeutc Hldng Inc generates a -148.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 3/100.
Sonnet Biotherapeutc Hldng Inc scores -13.93, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.6M) relative to total liabilities ($4.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sonnet Biotherapeutc Hldng Inc passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Sonnet Biotherapeutc Hldng Inc generates $0.80 in operating cash flow (-$12.8M OCF vs -$16.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Sonnet Biotherapeutc Hldng Inc generated $1.0M in revenue in fiscal year 2025. This represents an increase of 5268.8% from the prior year.
Sonnet Biotherapeutc Hldng Inc's EBITDA was -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.8% from the prior year.
Sonnet Biotherapeutc Hldng Inc reported -$16.0M in net income in fiscal year 2025. This represents a decrease of 115.3% from the prior year.
Sonnet Biotherapeutc Hldng Inc earned $-3.95 per diluted share (EPS) in fiscal year 2025. This represents an increase of 65.2% from the prior year.
Cash & Balance Sheet
Sonnet Biotherapeutc Hldng Inc held $5.1M in cash against $0 in long-term debt as of fiscal year 2025.
Sonnet Biotherapeutc Hldng Inc had 7M shares outstanding in fiscal year 2025. This represents an increase of 988.3% from the prior year.
Margins & Returns
Sonnet Biotherapeutc Hldng Inc's operating margin was -1584.4% in fiscal year 2025, reflecting core business profitability. This is up 62033.5 percentage points from the prior year.
Sonnet Biotherapeutc Hldng Inc's net profit margin was -1601.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 38328.2 percentage points from the prior year.
Sonnet Biotherapeutc Hldng Inc's ROE was -148.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Sonnet Biotherapeutc Hldng Inc invested $8.4M in research and development in fiscal year 2025. This represents an increase of 45.6% from the prior year.
SONN Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $1.0M | N/A | N/A | N/A | $19K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $2.4M+28.7% | $1.9M-0.1% | $1.9M | N/A | $1.7M-20.3% | $2.2M+236.5% | $644K |
| SG&A Expenses | N/A | $1.4M-41.1% | $2.3M+19.4% | $2.0M | N/A | $1.8M+5.9% | $1.7M+160.4% | $653K |
| Operating Income | N/A | -$3.8M+10.0% | -$4.2M-48.4% | -$2.8M | N/A | -$3.5M+8.8% | -$3.9M-202.5% | -$1.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | $158K | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$3.8M-8.2% | -$3.5M-10.5% | -$3.2M | N/A | -$3.5M-1059.3% | $365K+131.3% | -$1.2M |
| EPS (Diluted) | N/A | $-0.95-6.7% | $-0.89+42.9% | $-1.56 | N/A | $-5.57-1028.3% | $0.60+124.4% | $-2.46 |
SONN Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.9M+624.2% | $2.1M-46.4% | $3.8M-46.6% | $7.2M+159.2% | $2.8M-52.2% | $5.8M-1.9% | $5.9M+10.7% | $5.3M |
| Current Assets | $14.3M+986.9% | $1.3M-59.5% | $3.3M-51.6% | $6.7M+217.5% | $2.1M-58.7% | $5.1M-1.8% | $5.2M+13.0% | $4.6M |
| Cash & Equivalents | $5.1M+1493.6% | $321K-84.4% | $2.1M-57.6% | $4.9M+3152.8% | $149K-95.8% | $3.6M-6.1% | $3.8M+25.3% | $3.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | $500K | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.1M-19.7% | $5.1M+60.7% | $3.2M+0.9% | $3.1M-3.4% | $3.3M+2.5% | $3.2M+11.3% | $2.9M+3.2% | $2.8M |
| Current Liabilities | $4.1M-19.7% | $5.1M+60.7% | $3.2M+1.7% | $3.1M-2.8% | $3.2M+3.2% | $3.1M+12.5% | $2.8M+4.2% | $2.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $10.8M+454.1% | -$3.0M-560.0% | $662K-83.6% | $4.0M+931.0% | -$486K-118.6% | $2.6M-14.3% | $3.1M+18.7% | $2.6M |
| Retained Earnings | -$133.7M-4.4% | -$128.1M-3.0% | -$124.3M-2.9% | -$120.8M-2.7% | -$117.7M-2.7% | -$114.6M-3.2% | -$111.0M+0.3% | -$111.4M |
SONN Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.7M-223.3% | -$1.8M+28.8% | -$2.5M+15.1% | -$2.9M+8.2% | -$3.2M-3.3% | -$3.1M-524.1% | $724K+123.4% | -$3.1M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | N/A | N/A | $0 | N/A | N/A | N/A |
| Financing Cash Flow | $18.7M+88843.6% | $21K+106.6% | -$319K-104.2% | $7.6M+3347.6% | -$235K-108.2% | $2.8M+6850.6% | $41K-98.9% | $3.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SONN Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -284.9% | N/A | N/A | N/A | -6866.1% |
| Net Margin | N/A | N/A | N/A | -316.1% | N/A | N/A | N/A | -6273.5% |
| Return on Equity | N/A | N/A | -527.1%-448.8pp | -78.3% | N/A | -133.9%-145.9pp | 12.0%+57.4pp | -45.4% |
| Return on Assets | N/A | -183.7%-92.7pp | -91.0%-47.0pp | -44.0% | N/A | -60.5%-66.6pp | 6.2%+28.1pp | -21.9% |
| Current Ratio | 3.50+3.2 | 0.26-0.8 | 1.03-1.1 | 2.15+1.5 | 0.66-1.0 | 1.65-0.2 | 1.89+0.1 | 1.74 |
| Debt-to-Equity | 0.38+2.1 | -1.67-6.5 | 4.79+4.0 | 0.78+7.5 | -6.70-7.9 | 1.21+0.3 | 0.93-0.1 | 1.07 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Sonnet Biotherapeutc Hldng Inc's annual revenue?
Sonnet Biotherapeutc Hldng Inc (SONN) reported $1.0M in total revenue for fiscal year 2025. This represents a 5268.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sonnet Biotherapeutc Hldng Inc's revenue growing?
Sonnet Biotherapeutc Hldng Inc (SONN) revenue grew by 5268.8% year-over-year, from $19K to $1.0M in fiscal year 2025.
Is Sonnet Biotherapeutc Hldng Inc profitable?
No, Sonnet Biotherapeutc Hldng Inc (SONN) reported a net income of -$16.0M in fiscal year 2025, with a net profit margin of -1601.2%.
What is Sonnet Biotherapeutc Hldng Inc's EBITDA?
Sonnet Biotherapeutc Hldng Inc (SONN) had EBITDA of -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sonnet Biotherapeutc Hldng Inc's operating margin?
Sonnet Biotherapeutc Hldng Inc (SONN) had an operating margin of -1584.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sonnet Biotherapeutc Hldng Inc's net profit margin?
Sonnet Biotherapeutc Hldng Inc (SONN) had a net profit margin of -1601.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sonnet Biotherapeutc Hldng Inc's return on equity (ROE)?
Sonnet Biotherapeutc Hldng Inc (SONN) has a return on equity of -148.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sonnet Biotherapeutc Hldng Inc's operating cash flow?
Sonnet Biotherapeutc Hldng Inc (SONN) generated -$12.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Sonnet Biotherapeutc Hldng Inc's total assets?
Sonnet Biotherapeutc Hldng Inc (SONN) had $14.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Sonnet Biotherapeutc Hldng Inc spend on research and development?
Sonnet Biotherapeutc Hldng Inc (SONN) invested $8.4M in research and development during fiscal year 2025.
What is Sonnet Biotherapeutc Hldng Inc's current ratio?
Sonnet Biotherapeutc Hldng Inc (SONN) had a current ratio of 3.50 as of fiscal year 2025, which is generally considered healthy.
What is Sonnet Biotherapeutc Hldng Inc's debt-to-equity ratio?
Sonnet Biotherapeutc Hldng Inc (SONN) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sonnet Biotherapeutc Hldng Inc's return on assets (ROA)?
Sonnet Biotherapeutc Hldng Inc (SONN) had a return on assets of -107.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sonnet Biotherapeutc Hldng Inc's cash runway?
Based on fiscal year 2025 data, Sonnet Biotherapeutc Hldng Inc (SONN) had $5.1M in cash against an annual operating cash burn of $12.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sonnet Biotherapeutc Hldng Inc's Altman Z-Score?
Sonnet Biotherapeutc Hldng Inc (SONN) has an Altman Z-Score of -13.93, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sonnet Biotherapeutc Hldng Inc's Piotroski F-Score?
Sonnet Biotherapeutc Hldng Inc (SONN) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sonnet Biotherapeutc Hldng Inc's earnings high quality?
Sonnet Biotherapeutc Hldng Inc (SONN) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Sonnet Biotherapeutc Hldng Inc?
Sonnet Biotherapeutc Hldng Inc (SONN) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.